gms | German Medical Science

102. Jahrestagung der DOG

Deutsche Ophthalmologische Gesellschaft e. V.

23. bis 26.09.2004, Berlin

Adjuvant topical interferon alpha-2b-treatment for epithelial tumors of ocular surface

Meeting Abstract

  • corresponding author T.A. Fuchsluger - Dept. of Ophthalmology, Essen University Hospital
  • C. Hintschich - Dept. Of Ophthalmology, Ludwig-Maximilian-University, Munich
  • T. Hudde - Dept. of Ophthalmology, Essen University Hospital
  • K.P. Steuhl - Dept. of Ophthalmology, Essen University Hospital
  • D. Meller - Dept. of Ophthalmology, Essen University Hospital

Evidenzbasierte Medizin - Anspruch und Wirklichkeit. 102. Jahrestagung der Deutschen Ophthalmologischen Gesellschaft. Berlin, 23.-26.09.2004. Düsseldorf, Köln: German Medical Science; 2004. Doc04dogFR.11.01

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter: http://www.egms.de/de/meetings/dog2004/04dog258.shtml

Veröffentlicht: 22. September 2004

© 2004 Fuchsluger et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielfältigt, verbreitet und öffentlich zugänglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

Objective

To evaluate the role of topical interferon alpha-2b in the adjuvant treatment of corneal and conjunctival tumors.

Methods

Non-comparative, prospective, interventional case series. Eight patients with histologically proven conjunctival intraepithelial neoplasia (CIN), recurrence after primary excision and defect covering with amnion membrane or squamous cell carcinoma were given adjuvant local therapy with interferon (IFN) alpha-2b eye drops 5 x times a day, over 6 weeks (1 Million IU/ml Intron A, Schering). In situ-hybridisation technique was used to search for the presence of human papillomavirus (HPV) in 5 cases. Small meshed follow-up was undertaken clinically and photographically for evidence of tumor recurrence.

Results

In period of follow-up (3-37 months, March 2004) no clinical evidence of recurrence with only limited treatment side effects like mild conjunctival hyperemia could be recorded after six weeks of interferon. Other than reported by Scott et al. (using PCR technique) HPV 16/18 could be detected in only one CIN specimen of our patient collective (using in situ-hybridisation technique).

Conclusions

The combination of excisional biopsy and adjuvant topical interferon alpha-2b application seems to be an effective and safe treatment of epithelial tumors of the ocular surface. This combined treatment seems to be a therapeutical option to topical interferon alpha-2b treatment alone, more destructive approaches like radiation and cryotherapy or treatment with antimetabolites like 5-fluorouracill or mitomycin C.